Clinical trialsCompany release

Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns

🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026

The oncology developer reported Q3 2026 results alongside clinical progress for LP-184 and LP-300, a roughly $4.0M offering and a leadership change.

Lantern Pharma reported its third-quarter 2026 results on 18 November, pairing the financial update with progress on two clinical programmes and a change at the top of the company.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Lantern Pharma Inc. ↗

Article written by VigiEye from the official source (Lantern Pharma Inc.). Claims are the company's own. AI-assisted; check the source before acting.